Development and Validation of HPTLC Method for Simultaneous Analysis of Lopinavir and Ritonavir in their Combined Tablet Dosage Form

Abstract

Simultaneous quantification of Lopinavir and Ritonavir in tablet by HPTLC method was developed and validated. The chromatograms were developed using a mobile phase of Chloroform: 1, 4 -Dioxane (7:3 %v/v) on pre-coated plate of silica gel GF aluminum TLC plate and quantified by densitometric absorbance mode at 210 nm. The R f value for lopinavir and ritonavir was 0.74 and 0.58 respectively. The linearity of the method was found to be within the concentration range of 160-960 ng/spot for Lopinavir and for Ritonavir, it was 40-240 ng/spot. The lower limits of detection and quantification were 9.56 ng/spot and 28.96 ng/spot for Lopinavir and 6.82 ng/spot and 20.66 ng/spot for Ritonavir. The method was also validated for precision, specificity and recovery. This developed method was used to analyze fixed-dose tablet (Lopimune, Cipla Ltd) sample of Lopinavir and Ritonavir.

Development and Validation of Stability-Indicating UPLC-TUV Method for Simultaneous Estimation of Darunavir and Ritonavir in Bulk and Tablet Dosage Form

“…A literature survey revealed that there are several methods for the determination of DAR (Babu et al, 2013;Eswarudu et al, 2018) alone and DAR combined with other drugs also reported (Nalini et al, 2016;Fayet et al, 2009). The different analytical methods for the estimation of RIT (Behera et al, 2011;Koppala et al, 2015) alone and combined with other drugs have been reported (Mardia et al, 2012;Saritha et al, 2013). There are very few analytical methods for the simultaneous determination of DAR and RIT estimation are reported (Damle and Deosthali, 2016;Prathap et al, 2018).…”